,27 Inhibition of MAGL (monoacylglycerol lipase – enzyme degrading endocannabinoid 2-arachidonyl glycerol) has been proposed as a potential therapeutic approach for treatment of diverse neurological and neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and traumatic brain injury.28 Here, MGLL is linked to Parkinson disease.